Montelucaste Pharmakern (Montelukast)

Montelukast, a leukotriene receptor antagonist, is used to manage conditions driven by leukotriene‑mediated inflammation and bronchoconstriction.

• Asthma: reduces frequency of daytime and nighttime symptoms, decreases need for rescue inhalers, and improves overall lung function.
• Allergic rhinitis: alleviates nasal congestion, sneezing, itching and watery discharge, improving daily comfort and sleep quality.
• Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity, reducing cough and shortness of breath during and after exercise.
• Chronic airway inflammation: helps control leukotriene‑driven inflammation, contributing to long‑term asthma stability.

• Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells, mast cells and eosinophils. By antagonizing this receptor, it prevents leukotriene‑D4 and related mediators from binding, thereby inhibiting bronchoconstriction, vascular permeability and inflammatory cell recruitment that contribute to asthma and allergic rhinitis symptoms. The inhibition reduces airway edema and mucus secretion, supporting improved airflow and symptom control. This effect is sustained with once‑daily dosing, providing consistent receptor coverage over 24 hours.

Montelukast is generally well tolerated, but like all medicines it may cause adverse reactions.

Common Side Effects

• Headache
• Abdominal pain
• Cough
• Nasopharyngitis

Serious or Rare Side Effects

• Neuropsychiatric events such as agitation, depression or suicidal thoughts
• Severe allergic reactions including rash, urticaria, angioedema or anaphylaxis
• Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome)

When prescribing Montelukast, consider the following precautions:

• Pregnancy: consult a healthcare provider as safety data are limited.
• Breastfeeding: assess risk‑benefit; the drug may be excreted in milk.
• Renal impairment: monitor because the drug is excreted unchanged.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Concomitant use with phenobarbital or rifampin may reduce exposure.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Montelukast may interact with other medicines; review patient medication lists carefully.

Major Interactions (Avoid)

• Phenobarbital, rifampin, carbamazepine: induce metabolism and markedly reduce plasma levels.

Moderate Interactions (Monitor Closely)

• Ketoconazole, erythromycin: may increase montelukast levels modestly.
• Warfarin: monitor INR as anticoagulant effect may be enhanced.
• Theophylline: observe for possible increased side effects.
• Fluconazole: may increase exposure to montelukast.